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without Septo-Optic Dysplasia (SOD).  So far there is no clear genotype-phenotype 57 
correlation. 58 
Patients and Results: We report three different recessive loss-of-function mutations in three 59 
unrelated families with CPHD and no midline defects or SOD.  A homozygous p.R160C 60 
mutation was found by Sanger sequencing in two siblings from a consanguineous family. 61 
These patients presented with ACTH, TSH and GH deficiencies, severe anterior pituitary 62 
hypoplasia (APH) or pituitary aplasia (PA) and normal posterior pituitary. The p.R160C 63 
mutation was previously reported in a case with SOD, CPHD and ectopic posterior pituitary 64 
(EPP).  Using exome sequencing, a homozygous p.I26T mutation was found in a Brazilian 65 
patient born to consanguineous parents.  This patient had evolving CPHD, normal ACTH, 66 
APH and normal posterior pituitary (NPP).  A previously reported patient homozygous for 67 
p.I26T had evolving CPHD and EPP.  Finally, we identified compound heterozygous 68 
mutations in HESX1, p.[R159W];[R160H],  in a patient with PA and CPHD.  We showed that 69 
both of these mutations abrogate the ability of HESX1 to repress PROP1-mediated 70 
transcriptional activation. A patient homozygous for p.R160H was previously reported in a 71 
patient with CPHD, EPP, APH.   72 
Conclusion: These three examples demonstrate that HESX1 mutations cause variable clinical 73 
features in patients, which suggests an influence of modifier genes or environmental factors 74 
on the phenotype. 75 
Introduction 76 
Congenital hypopituitarism refers to the deficiency of two or more pituitary hormones, and it 77 
is caused by mutations in one of several genes implicated in pituitary development, such as 78 
HESX1, OTX2, PROP1, POU1F1, LHX3, LHX4, SOX2, SOX3 and GLI2.1, 2  In some patients 79 
the hormone deficiency may present as part of a syndrome with abnormalities in structures 80 
that share a common embryological origin with the pituitary gland, such as the eye and the 81 
forebrain. 82 
        HESX1 encodes a paired-like homeobox transcription factor that was first identified in 83 
embryonic stem cells.3, 4 HESX1 is one of the earliest known markers of the pituitary 84 
primordium.  It can be detected in the anterior forebrain from 7.5 to 8.5 days post coitum 85 
(d.p.c.) and in the Rathke’s pouch from 8.5 to 13.5 days d.p.c.  Expression of HESX1 is 86 
important for the early determination and differentiation of pituitary gland,5, 6 as well as 87 
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        A number of autosomal dominant and recessive mutations in HESX1 have been 89 
described in patients with a broad spectrum of phenotypes ranging from isolated growth 90 
hormone deficiency (IGHD), combined pituitary hormone deficiencies (CPHD) to septo-optic 91 
dysplasia (SOD).6, 9-11 Magnetic Resonance Images (MRI) also reveal variable effects.  The 92 
anterior pituitary can be hypoplastic or aplastic, and the posterior pituitary can be ectopic or 93 
eutopic.  No clear genotype-phenotype correlation s obvious among the cases with HESX1 94 
mutations, but there is a trend that the recessive mutations cause more severe phenotypes and 95 
appear to be fully penetrant while heterozygous mutations may be associated with milder 96 
phenotypes and reduced penetrance.6, 9, 10, 12-14 97 
        The approach of Sanger sequencing of candidate genes hasled to the identification of 98 
most of the known genetic causes of hypopituitarism.  It is clear that hypopituitarism is a 99 
genetically heterogeneous condition.  The mutations in the reported genes account for less 100 
than 20% of the cases.  Thus, candidate gene screening has a low detection rate.  The recent 101 
introduction of massive-parallel sequencing methods now offer the promise of detecting 102 
mutations in known candidate genes, as well as the identification of novel genes implicated in 103 
congenital hypopituitarism.  In this study we report the identification of mutations in HESX1 104 
in patients from three unrelated families with CPHD without midline defects or SODs.  This 105 
is among the first examples of applying next-generation sequencing techniques to obtain a 106 
molecular diagnosis for hypopituitarism in humans.15, 16 107 
 108 
Subjects and Methods 109 
Four patients from three unrelated families were recruited in this study(Figure 1, Table 1).  111 
Two siblings (1.1 and 1.2) in Family 1 were born to consanguineous parents of Middle-112 
Eastern origin.  Patients 1.1 and 1.2 were initially diagnosed in the Middle East and then 113 
treated at Great Ormond Street Hospital for Children, London, UK. Patient 2.1 in Family 2 114 
was born to a Brazilian consanguineous family, and she was diagnosed and treated t the 115 
Clinical Hospital of the Faculty of Medicine of the University of São Paulo, São Paulo, 116 
Brazil.  Family 3 was diagnosed and treated at Floating Hospital for Children at Tufts 117 
Medical Center, Boston, MA, USA.
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        Patient studies were approved by the ethical committees at each institution.  Patient 1.1 119 
and 1.2 were approved by a committee functioning according to the 3rd edition of the 120 
Guidelines on the Practice of Ethical Committees in Medical Research, issued by the Royal 121 
College of Physicians of London. Copies of the MRC recommendations can be obtained from 122 
the Medical Research Council.   Patient 2.1 was approved by the National Research Ethics 123 
Commission (CONEP) and by the Ethics Committee in Research (CEP) from the University 124 
of São Paulo, Medical School, São Paulo, Brazil functioning according to the Resolution No. 125 
466/2012 which deals with research and testing in humans adopted by the Plenary of the 126 
National Health Council (CNS) in 240ª ordinary meeting in December 2012.   Exome 127 
sequencing of de-identified patient samples was approved by the IRBMED at University of 128 
Michigan. 129 
Patient DNA samples from families 2 and 3 were subjected to whole exome sequencing. 131 
Exome capture was performed by the U-M Sequencing Core using the Nimblegen SeqCap 132 
EZ Human Exome Library v3.0, targeting a total of 64 Mb of the genome.  Paired-end 100-133 
base sequencing data were collected using an Illumina HiSeq2000 system. Exome capture 134 
and sequencing for two patients, namely 2.1 and 3.2, were performed in the same batch.  135 
BWA v0.5.9 was used to align Illumina reads to the 1000 Genomes Phase 1 reference 136 
mapped to GRCh37.  Read pairs that mapped to multiple locations were removed; most of 137 
these locations contain highly repetitive sequences and are inaccessible to short-read 138 
sequencing.  PICARD v1.74 was used to remove duplicate read pairs. Variant detection for 139 
both SNVs and small indels (<10 nt) were performed by the GATK Haplotype Caller v3.3. 140 
Multi -sample joint calling with 688 in-house exome samples was performed to remove the 141 
sequencing artifacts. 142 
Exome Sequencing and Variant Calling 130 
Sanger sequencing was used to analyze the HESX1 gene in patients from Family 1. The 144 
variants identified in Family 2 and 3 by exome sequencing were confirmed by Sanger 145 
sequencing. 146 
Sanger Sequencing 143 
To detect copy number variation, we performed genotyping on the two DNA samples for 148 
patients 2.1 using Illumina’s HumanOmniExpressExome_8v1_A at the University of 149 
Michigan Sequencing Core.  150 
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pCMV6-Entry-human HESX1 (Myc-DDK-tagged) was purchased from OriGene (Cat. No. 152 
RC210107, OriGene Technologies, MD).  The c.475C>T and c.479G>A changes were 153 
introduced into the HESX1 cDNA sequence by using QuickChange II XL Site-Directed 154 
Mutagenesis Kit (Cat. No. 200521, Stratagene).  The HESX1 cDNA sequences have been 155 
checked to confirm that except for c.475C>T and c.479G>A, no other mutations were 156 




E4 firefly luciferase reporter, pcDNA3.1(-)-human PROP1 157 
have been described and used previously.   pcDNA3.1(-) and pRL-TK renilla luciferase 158 
reporter vectors were from Invitrogen and Promega, respectively.  159 
COS-7 cells were cultured in DMEM supplemented with 10% fetal bovine serum and 1% 161 
penicillin-streptomycin. Transient transfections were carried out using FuGENE6 (Promega), 162 
following the manufacturer’s protocol with modifications. Briefly, 1 x 105 cells were seeded 163 
into each well on a 24-well plate 24 hours before transfection. Cells were transfected with 10 164 
ng of pRL-TK renilla luciferase vector (Promega) to control for transfection efficiency and 165 
200 ng of (P3)
Cell culture and Transfections 160 
6
11E4 firefly luciferase reporter.   The DNA concentration of the other 166 
transfected plasmids varied depending on experimental protocol as indicated in the figure 167 
legends, but the total amount of DNA transfected per well was normalized to 400 ng by 168 
addition of the appropriate amount of empty expression vector. Cells were incubated and 169 
collected 48 hrs later and assayed for luciferase activity using the dual-luciferase protocol on 170 
GLOMAX 96 Microplate Luminometer (Promega).  171 
 172 
Results 173 
Clinical Characteristics 174 
Patients 1.1 and 1.2 are consanguineous siblings who presented with hypoglycaemic seizures 175 
in the neonatal period and complete ACTH, TSH, GH and prolactin deficiencies 176 
(undetectable cortisol, free thyroxine 2.42 pmol/L in 1.2, TSH <0.005 in 1.2, undetectable 177 
IGF1 and GH 0.01 mU/L in 1.2, and prolactin <11 mU/L in 1.2). MRI revealed severe 178 
anterior pituitary hypoplasia (APH) and eutopic posterior pituitary. In both siblings, 179 
thyroxine and hydrocortisone were commenced in the neonatal period and growth hormone 180 
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pubertal induction at the age of 12 years. The younger sibling, currently 6 years old, is too 182 
young to assess the hypothalamo-pituitary-gonadal axis. (Figure 1, Table 1) 183 
        Patient 2.1 was the daughter of first-degree cousins.  She first presented with short 184 
stature (height 125.9 cm, -6.0 standard deviation score (SDS)) at 17.2 years of age, with a 185 
weight of 32.6 kg (1.0 SD for stature age). Her bone age was delayed by 4 years. Her mid-186 
parental height (MPH) was 150 cm (-2.03 SDS). Clinical investigations revealed GH and 187 
gonadotropin deficiencies (peak GH <0.1 ng/ml, FSH 1.3 mU/mL, LH 0.7 mU/mL) and 188 
tertiary hypothyroidism (Free T4 0.81 ng/dL, basal TSH 5.7 mU/mL with late response to 189 
TRH stimulation). She was treated with recombinant human GH and thyroxine.  Puberty was 190 
induced at 21.4 years old and her final height was 151.2 cm (-1.83 SDS), well within her 191 
target height range.  She has not as yet developed ACTH deficiency. MRI of the pituitary 192 
gland showed a normal stalk, anterior pituitary hypoplasia and a eutopic posterior pituita y. 193 
(Figure 1, Table 1) 194 
        Patient 3.2 was born to a non-consanguineous pedigree with a previously affected sister 195 
(Figure 1). Detailed early clinical course of this patient has previously been reported.17  196 
Briefly, patient 3.2 is a Caucasian boy.  His older sister (3.1) developed hypoglycaemia and 197 
died on the first day of life.  A postmortem examination revealed absence of the anterior 198 
pituitary and atrophy of the adrenal glands. At eight hours of age, patient 3.2 became 199 
lethargic and cyanotic, and had a generalized seizure. Because of the similarity in 200 
presentation to that of his sister, a presumptive diagnosis of hypopituitarism was ade, and 201 
he was treated with glucose and hydrocortisone.  He was subsequently treated for 202 
hypothyroidism and growth hormone deficiency, and he achieved normal developmental 203 
milestones.  He failed to develop secondary sexual characteristics as a teenager. His 204 
luteinizing hormone (LH), follicle stimulating hormone (FSH), and testosterone 205 
concentrations remained in the prepubertal range on repeated tests. MRI confirmed absence 206 
of the anterior pituitary and presence of the posterior pituitary gland.  His final height was 207 
174 cm.  Several years later, at the age of 30 years, he died after developing severe 208 
gastroenteritis with vomiting and diarrhoea. (Figure 1, Table 1) 209 
Genetic Analysis 210 
Sanger sequencing was performed to identify the homozygous p.R160C mutation in HESX1 211 
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        Whole exome sequencing (WES) was performed on the genomic DNA samples from 213 
patients 2.1 and 3.2. Alignment of the reads and variant calling were performed as described 214 
in Methods. For this study, we concentrated on potentially d maging SNVs (nonsense, 215 
missense, stop loss, splicing change, frameshift, etc.) and small indels (<10 nt). Fil tering 216 
steps were made according to following criteria: reading depth of variants (≥10), minor allele 217 
frequency in ExAC, ESP and 1000G public databases (≤1% for homozygous variants and 218 
≤3% for compound heterozygous variants), prediction that the variant has a deleterious effect 219 
on the gene function by at least one software program, RVIS percentile (≤75%), (CADD 220 
Phred score (≥15) and GERP++ score (≥4) (Supplement Figure 1).  Sanger sequencing was221 
used to confirm the candidate variants. 222 
        Because patient 2.1 is from a consanguineous family, the most compelling variants are 223 
located in the runs of homozygosity (ROH) regions and transmitted in a recessive inheritance 224 
pattern.  We identified two rare, homozygous variants in the ROH regions: rs28936416 225 
(c.77T>C, p.I26T) in HESX1 and rs141318879 (c.888G>A, p.M296I) in HMGCLL1. A 226 
CPHD patient homozygous for c.77T>C, p.I26T in HESX1 gene was previously reported, and 227 
the variant was shown to impair the transcriptional repression properties of HESX1.11  228 
HMGCLL1 gene encodes an isoenzyme of human HMG-CoA lyase and is located in the 229 
endoplasmic reticulum (ER).18  There is no report on variants in HMGCLL1 gene causing 230 
hypopituitarism. Patient 2.1 was also compound heterozygous for six genes (ANGPTL1, 231 
EPHA1, CDCC88B, AGAP2, FASN, MBD1) which carry at least one allele passing all the 232 
filtering criteria, but none of them is located in the ROH regions of patient 2.1’s genome.  No 233 
variants were detected in other known genes for CPHD or IGHD.  Therefore, HESX1 234 
c.77T>C, p.I26T is the most-likely pathogenic variant for the phenotype in patient 2.1.  235 
        Patient 3.2 was the second affected child n a family with non-consanguineous parents.  236 
Therefore, we first considered a recessive inheritance pattern.  We did not detect any 237 
homozygous variants, but eight compound heterozygous variants were found in four genes on 238 
the autosomal chromosomes that passed through the filtering steps.  These four genes are 239 
HESX1, AK9, H6PD, and CCDC168.  Among them, only mutations in HESX1 are known to 240 
cause CPHD and/or SOD.  The two variants we found in HESX1 are c.475C>T, p.R159W 241 
and c.479G>A, p.R160H.  We verified that the two variants are truly in trans using the 242 
Integrative Genomics Viewer (IGV) of individual reads.19  Both p.R159W and p.R160H 243 
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p.R160H change was previously reported to cause CPHD.20   This is the first report of the 245 
variant c.475C>T, p.R159W in a CPHD patient. The minor allele frequency (MAF) of the 246 
p.R159W change is less than 0.002% (ExAC database), which means this variant is 247 
extremely rare in the general population. All of the prediction software programs we used 248 
(SIFT, PolyPhen-2, Mutation Taster, Mutation Assessor and FATHMM) predict tha the 249 
p.R159W change has a deleterious effect on HESX1 function. Thus, the compound 250 
heterozygous variants p.[R159W];[R160H] are the most likely pathogenic causes for the 251 
phenotype of patient 3.2. 252 
Functional Studies  253 
HESX1 acts as a transcriptional repressor by suppressing the activity of PROP1.9, 11, 21 254 
Mutations in either the homeodomain or the engrailed homology (eh) domain of HESX1 255 
impair this repressive ability.9, 11  To test if p.R159W and p.R160H substitutions affect the 256 
repressive ability of HESX1, Cos-7 cells were transiently transfected with plasmids 257 
expressing PROP1, normal HESX1 (HESX1-WT), HESX1-p.R159W and HESX1-p.R160H. 258 
These expression vectors were co-transfected with the reporter construct (pGL3) containing 6 259 
tandem paired homeodomain conse sus DNA binding sites (P3)6 upstream of the  E4 260 
 272 
promoter activating the expression of firefly luciferase gene. As expected, PROP1 activated 261 
reporter gene expression, and HESX1-WT, HESX1-p.R159W and HESX1-p.R160H have no 262 
effect on transcription when tested individually (Figure 2). When equal amounts of HESX1-263 
WT were co-transfected with PROP1, PROP1 activation was repressed by ~50%. Neither 264 
HESX1-p.R159W nor HESX1-p.R160H were able to repress PROP1 activity.  Transfection 265 
of equal amounts of HESX1-p.R159W and HESX1-p.R160H together with PROP1 were 266 
carried out to mimic the compound heterozygous status of the HESX1 mutations in patient 267 
3.2.  The combination of p.R159W and p.R160H was also unable to repress PROP1 268 
activation (Figure 2a). This lack of repression is not due to different expression levels of 269 
HESX1 proteins, as HESX1-WT, HESX1-p.R159W and HESX1-p.R160H were expressed at270 
comparable levels in the cells as determined by Western Blot analysis (Figure 2b). 271 
Discussion 273 
Congenital hypopituitarism (CPHD) occurs in 1:4,000 to 10,000 births, and the molecular 274 
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Mutations in HESX1 apparently account for 8% or less of CPHD cases.22, 23 Mutations were 276 
initially described in patients with SOD, and later in patients presenting with non-syndromic 277 
hypopituitarism.6, 9, 11, 24 278 
        In this study, we identified a homozygous HESX1 p.R160C mutation by Sanger 279 
sequencing in two CPHD patients without SOD from a consanguineous Middle Eastern 280 
pedigree. This p.R160C mutation was previously described in two siblings with CPHD and 281 
SOD from consanguineous patients of Pakistani origin.6  The p.R160C change is located in 282 
the homeodomain, and EMSA analysis showed that it abrogates DNA binding, consistent 283 
with loss of function.6, 9  The discrepancy in the presence of SOD in the two families with the 284 
same mutation suggests the effects of other genes, vironment, or chance in enhancing or 285 
suppressing the severity of the phenotype.   286 
        We used exome sequencing to identify a homozygous p.I26T mutation in HESX1 in a 287 
Brazilian patient who was born to consanguineous parents, and presented with CPHD and a 288 
eutopic posterior pituitary lobe.  This phenotype differs from that previously reported for a 289 
homozygous p.I26T mutation in an unrelated Brazilian patient from consanguineous parents. 290 
That patient had ACTH deficiency and an ectopic posterior pituitary gland.11  The p.I26T 291 
mutation is located in the engrailed homology domain, which is required for recruitment of 292 
the co-repressor TLE1, and functional analysis revealed that the mutation decreases the 293 
repressive function of the protein.11, 21  The mutation p.I26T has an allele frequency at 294 
0.002% in the general population and none in homozygous state (data from ExAC).  295 
        We identified a compound heterozygous HESX1 mutation p.[R159W];[R160H] in a 296 
patient with CPHD, including aplastic anterior lobe but no SOD, using exome sequencing, 297 
and we demonstrated that each of these mutations impairs the repressive function of HESX1. 298 
In previous studies, two patients from different consanguineous families were reported to be 299 
homozygous for HESX1 p.R160H, but no functional studies were done.20, 25  Those patients 300 
presented with hypoplastic anterior pituitary with deficiencies of GH, TSH, ACTH and 301 
prolactin.  302 
        Genetically engineered mice provide an opportunity to assess the variability in 303 
presentation amongst individuals of identical genotype through generation of large cohorts 304 
and the effects of different genetic backgrounds by outcrossing to different inbred strains.  A 305 
comparison of genetically engineered mice homozygous for the Hesx1null, Hesx1R160C and 306 
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is a hypomorph.26  Despite efforts to normalize the genetic background, there was some 308 
variability in presentation amongst animals with the same genotype. 5% of homozygous 309 
Hesx1null mice have profound abnormalities that include absent telencephalic vesicles, eyes, 310 
olfactory placodes and Rathke’s pouches.6 The majority of Hesx1R160C/R160C and Hesx1I26T/I26T 311 
mice had eye defects and enlarged and bifurcated anterior pituitaries.  Telencephalic defects 312 
were detected in nearly 80% Hesx1R160C/R160C mice, but not in Hesx1I26T/I26T mice.  313 
Interestingly, neither Hesx1R160C/R160C nor Hesx1 I26T/I26T mice were deficient in the induction 314 
and differentiation of hormone-producing cells, although pituitary function could not be 315 
assessed because of lethality.26  The phenotypic variability among mice with the same 316 
genotype could be due to chance or the action of epigenetic or environmental factors that 317 
affect how the mutations express themselves phenotypically.27  Alternatively, the residual 318 
genetic variation in other genes and/or pathways may modify the severity of phenotypes.28  319 
The completely sequenced genomes of inbred mouse strains and the international 320 
Collaborative Cross (CC) project in mice would largely facilitate the mapping of the modifier 321 
genes.  322 
        To explain the phenotypic variation in humans, we need more comprehensive 323 
information about the patients’ phenomes and genomes. To discover genetic modifiers of a 324 
Mendelian trait by WES, an extreme phenotype study design and/or large sample sizes are 325 
required to achieve the statistical power that is needed.29 WES provides the ability to detect 326 
potential disease causing variants in the coding regions across the genome. Given that CPHD 327 
is a rare condition in the poulation and the known variants and genes only account for a 328 
minority of the cases, WES will improve the overall detection rate for CPHD mutations.  In a 329 
cohort of 23 unrelated CPHD patients currently undergoing WES at University of Michigan, 330 
only the 2 cases reported in this study were found to harbor pathogenic mutations in a known 331 
gene.  This detection rate is about 8.7%, which is higher than any other study screening for 332 
HESX1 mutations. WES obviously offers the advantage of identifying novel causes of CPHD 333 
and the potential for elucidating multi-genic mechanisms similar to those that have been 334 
observed in mice.28  335 
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Table and Figure Legends: 446 
Table 1: Clinical phenotype of patients harboring the HESX1 mutations.  447 
 448 
Figure 1: Pedigrees of families 1, 2 and 3.  Filled symbols represent family members with 449 
pituitary hormone deficiency.  Arrow points to the proband in family 3. 450 
 451 
Figure 2: Functional studies reveal failure of HESX1 compound heterozygous variants 452 
[p.R159W/p.R160H]  to repress PROP1 activity.  (a) Plasmid constructs carrying human 453 
PROP1, HESX1-WT, HESX1-p.R159W and HESX1-p.R160H were transfected individually 454 
or in combinations into COS-7 cells to measure the activation of firefly luciferase reporter. 455 
HESX1-WT, HESX1-p.R159W and HESX1-p.R160H have no effect on transcription by 456 
themselves. Equal amounts of HESX1-WT repress PROP1 activation by ~50%. Neither 457 
HESX1-p.R159W nor HESX1-p.R160H were able to repress PROP1 activity. The 458 
combination of p.R159W and p.R160H was also unable to repress PROP1 activation. The 459 
results represent the means of three independent experiments, each performed in triplicate.  460 
(b) Western blotting (WB) was performed to show that p.R159W and p.R160H mutations do 461 
not affect the protein expression level of HESX1 in the COS-7 transfected cells. 462 
 463 
Supplementary Material Legend: 464 
 465 
Supplemental Figure 1: Variant discovery and analysis.  It shows the multi-stage filtering 466 
strategy and the number of single nucleotide variants and insertion/deletions (SNVs + Indels) 467 
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Table 1: Summary of the clinical phenotypes and MRI findings of CPHD/SOD  
 
patients with HESX1 mutations related with this study 
Abbreviations: CPHD, combined pituitary hormone deficiency; SOD, septo-optic 
dysplasia; ONH, optic nerve hypoplasia; ACTH, adrenocorticotropin; FSH, follicle-
stimulating hormone; GH, growth hormone; LH, luteinizing hormone; TSH, thyroid-
stimulating hormone; APH, anterior pituitary hypoplasia; PA, pituitary aplasia; PP, 
posterior pituitary; EPP, ectopic posterior pituitary; NPP, normal posterior pituitary; NA, 
not available. 
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